BR112018074231A2 - compostos bicíclicos fundidos para o tratamento de doença - Google Patents

compostos bicíclicos fundidos para o tratamento de doença

Info

Publication number
BR112018074231A2
BR112018074231A2 BR112018074231-7A BR112018074231A BR112018074231A2 BR 112018074231 A2 BR112018074231 A2 BR 112018074231A2 BR 112018074231 A BR112018074231 A BR 112018074231A BR 112018074231 A2 BR112018074231 A2 BR 112018074231A2
Authority
BR
Brazil
Prior art keywords
disease
treatment
fused bicyclic
bicyclic compounds
compounds
Prior art date
Application number
BR112018074231-7A
Other languages
English (en)
Inventor
Mohan Raju
Anthony Pratt Benjamin
Original Assignee
Akarna Therapeutics, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akarna Therapeutics, Ltd. filed Critical Akarna Therapeutics, Ltd.
Publication of BR112018074231A2 publication Critical patent/BR112018074231A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Abstract

são aqui descritos compostos bicíclicos fundidos, composições e métodos para seu uso para o tratamento de doença.
BR112018074231-7A 2016-05-25 2017-05-25 compostos bicíclicos fundidos para o tratamento de doença BR112018074231A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662341483P 2016-05-25 2016-05-25
US201662341486P 2016-05-25 2016-05-25
US62/341,483 2016-05-25
US62/341,486 2016-05-25
PCT/US2017/034493 WO2017205633A1 (en) 2016-05-25 2017-05-25 Fused bicyclic compounds for the treatment of disease

Publications (1)

Publication Number Publication Date
BR112018074231A2 true BR112018074231A2 (pt) 2019-03-06

Family

ID=60411628

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018074231-7A BR112018074231A2 (pt) 2016-05-25 2017-05-25 compostos bicíclicos fundidos para o tratamento de doença

Country Status (13)

Country Link
US (1) US20200325140A1 (pt)
EP (1) EP3463372A4 (pt)
JP (1) JP2019520335A (pt)
KR (1) KR20190040140A (pt)
CN (1) CN109789149A (pt)
AU (1) AU2017270203A1 (pt)
BR (1) BR112018074231A2 (pt)
CA (1) CA3025326A1 (pt)
IL (1) IL263177A (pt)
MX (1) MX2018014034A (pt)
RU (1) RU2018145721A (pt)
SG (2) SG10202011665SA (pt)
WO (1) WO2017205633A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY192927A (en) * 2014-11-21 2022-09-15 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
WO2021067326A1 (en) * 2019-10-01 2021-04-08 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
CN112402430A (zh) * 2020-12-11 2021-02-26 大连医科大学 泽泻醇b-23-醋酸酯在预防和治疗急性肾损伤中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532235A (en) * 1995-01-17 1996-07-02 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
BRPI0412262A (pt) * 2003-07-23 2006-09-19 X Ceptor Therapeutics Inc derivados de azepina como agentes farmacêuticos
GB0513886D0 (en) * 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
KR20090094125A (ko) * 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Ｌｘｒ 및 ｆｘｒ 조절자
US20090131409A1 (en) * 2007-10-22 2009-05-21 Wyeth 1,4,5,6,7,8-HEXAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
US20090137554A1 (en) * 2007-10-22 2009-05-28 Wyeth 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
US20110263588A1 (en) * 2008-10-27 2011-10-27 Glaxo Group Limited Tricyclic compounds as glutamate receptor modulators
WO2014094357A1 (en) * 2012-12-21 2014-06-26 Abbvie Inc. Heterocyclic nuclear hormone receptor modulators
CA2980394A1 (en) * 2015-03-26 2016-09-29 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease

Also Published As

Publication number Publication date
RU2018145721A3 (pt) 2020-08-21
US20200325140A1 (en) 2020-10-15
CA3025326A1 (en) 2017-11-30
EP3463372A4 (en) 2019-11-13
KR20190040140A (ko) 2019-04-17
SG11201810292YA (en) 2018-12-28
WO2017205633A1 (en) 2017-11-30
MX2018014034A (es) 2019-08-29
IL263177A (en) 2018-12-31
AU2017270203A1 (en) 2019-01-03
CN109789149A (zh) 2019-05-21
EP3463372A1 (en) 2019-04-10
JP2019520335A (ja) 2019-07-18
RU2018145721A (ru) 2020-06-25
SG10202011665SA (en) 2020-12-30

Similar Documents

Publication Publication Date Title
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
BR112018008326A2 (pt) composições e métodos para o tratamento de câncer
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
BR112017007170A2 (pt) anticorpos anti-ox40 humanizados e suas utilizações
EA201800444A1 (ru) Производные майтанзиноида, их конъюгаты и способы использования
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
ECSP17034845A (es) Conjugados de anticuerpo- farmaco
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA201791884A1 (ru) Химерные антигенные рецепторы против dll3 и способы применения
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
CL2019001381A1 (es) Método para el tratamiento de glomeruloesclerosis segmentaria focal.
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
BR112018003928A2 (pt) métodos para o tratamento de doenças
BR112018009745A8 (pt) compostos heterocíclicos para o tratamento de doença
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
CO2018008249A2 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements